Phesi Global Data Analysis: Most Studied Disease Areas - January-June 2023
Phesi’s mid-year global analysis of all clinical trials conducted in the first six months of 2023 using Trial Accelerator™ reveals COVID-19 is no longer one of the top five most studied diseases. Depression has entered the top five while oncology occupies three of the top five positions. Discover the implications for trial design and execution by downloading our report.
Key highlights:
Solid tumors are now the most studied indication signalling a greater focus on oncology innovation
Depression has become the fourth most studied disease area
Phase II terminations continue sharp rise - almost a third of trials have been cancelled in Phase II
